Boston An independent LDT provider
NOTE:Immunovia has ceased commercialization of the IMMray PanCan-d test. More information available here:

Blinded Validation Study Performance and Improvement Studies

March 30, 2021

Presentations by: Patrik Dahlen, CEO, Thomas King, MD, PhD, Linda Mellby, PhD, Immunovia

Immunovia reports positive results of the blinded clinical validation of IMMray™ PanCan-d blood test for Stage I/II pancreatic cancers in familial/hereditary risk groups in USA – and improved test performance in detecting early stage pancreatic cancer in high risk symptomatic patients.

0:00 Introduction and Agenda
1:55 Immunovia reports historical breakthrough in early detection of pancreatic cancer in high risk groups
6:29 IMMray™ PanCan-d positive results in blinded validation study USA
13:56 Improved clinical performance of IMMray™ PanCan-d for high risk symptomatic patients
18:38 Conclusions and Next steps
26:20 Q&A Session